0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Predictors for Failure of Pneumocystis carinii Pneumonia Prophylaxis

Alfred J. Saah, MD, MPH; Donald R. Hoover, PhD, MPH; Yun Peng, MS; John P. Phair, MD; Barbara Visscher, MD, DrPH; Lawrence A. Kingsley, DrPH; Lewis K. Schrager, MD; Ellen Taylor; Joseph B. Margolick, MD, PhD; Richard Markham, MD; Justin McArthur, MBBS; Homayoon Farzadegan, PhD; Haroutune Armenian, MD, DrPH; Neil Graham, MBBS, MD; Joan S. Chmiel, PhD; Bruce Cohen, MD; Steven Wolinsky, MD; Roger Detels, MD; Barbara R. Visscher, MD, DrPH; John L. Fahey, MD; Janis V. Giorgi, PhD; Jan Dudley, MPH; Moon Lee, PhD; Pari Nishanian, PhD; Charles R. Rinaldo Jr, PhD; Monto Ho, MD; Phalguni Gupta, PhD; Allan Winkelstein, MD; Alvaro Mufloz, PhD; Noya Galai, PhD; Donald R. Hoover, PhD; Kenrad Nelson, MD; P. Jacobson Lisa, ScM; Sol Su, PhD; Lewis Schrager, MD; Richard A. Kaslow, MD, MPH; Mark J. VanRaden, MA; Daniela Seminara, PhD
JAMA. 1995;273(15):1197-1202. doi:10.1001/jama.1995.03520390057033.
Text Size: A A A
Published online

Objective.  —To identify clinical and epidemiological factors associated with failure of Pneumocystis carinii pneumonia (PCP) prophylaxis in those receiving primary and secondary prophylaxis.

Design.  —Longitudinal cohort study of participants infected with human immunodeficiency virus type 1 in the Multicenter AIDS Cohort Study who used PCP prophylaxis regimens after their T-helper lymphocyte counts had decreased to less than 0.200×109/L (200/μL).

Main Outcome Measure.  —Occurrence or recurrence of PCP.

Results.  —A total of 476 participants reported taking one or more of the following regimens: trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, and/or aerosolized pentamidine—367 as primary prophylaxis and 109 as secondary prophylaxis after a previous episode of PCP. A total of 92 (20%) developed PCP despite prophylaxis. The mean failure rates per person-year of follow-up were 16.0% for those receiving primary prophylaxis and 12.1% for those receiving secondary prophylaxis (P=.19). Median times to death after initiation of primary or secondary prophylaxis were 2.0 and 1.2 years, respectively. The main predictor for failure of PCP prophylaxis was profound T-helper lymphocytopenia; 86% of failures occurred after T-helper cell counts decreased to less than 0.075×109/L and 76% occurred after counts decreased to less than 0.050×109/L. In multivariate time-dependent analysis, when compared with counts between 0.100×109/L and 0.200×1009/L, the risk ratio for failure with counts less than 0.050×109/L was 2.90 (P<.001). Once T-helper cell counts were considered, fever was the only other health status indicator that predicted subsequent PCP (ie, a time-dependent risk ratio of 2.22; P=.01). Use of TMP-SMX as the prophylaxis regimen was protective but did not eliminate failure (ie, a time-dependent risk ratio of 0.55; P=.03).

Conclusions.  —These findings strongly support identifying improved methods of PCP prophylaxis once T-helper cell counts decrease to less than 0.075×109/L or 0.100×109/L. Given this severe degree of immunosuppression, an inherently more effective regimen against P carinii is required.(JAMA. 1995;273:1197-1202)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();